PXMD — Kuvatris Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $0.01m
- -$0.31m
Annual balance sheet for Kuvatris Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.025 | 1.12 | 0.444 | 1.9 | 4.71 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | — | — | 0 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.025 | 1.12 | 0.444 | 2.2 | 5.68 |
| Other Long Term Assets | |||||
| Total Assets | 0.025 | 1.12 | 0.649 | 2.2 | 5.68 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.123 | 5.75 | 10.8 | 2.1 | 1.8 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.123 | 5.75 | 10.8 | 2.1 | 2.3 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -0.098 | -4.63 | -10.1 | 0.109 | 3.39 |
| Total Liabilities & Shareholders' Equity | 0.025 | 1.12 | 0.649 | 2.2 | 5.68 |
| Total Common Shares Outstanding |